Abstract
Vasopressin has a multitude of functions and acts on a variety of receptors. It is subject to investigation as a rational therapy for septic shock and may have benefits in patients with acute kidney injury (AKI). Vasopressin can increase glomerular filtration rate, urine output, and creatinine clearance. Septic shock causes an initial surge then relative deficiency of vasopressin, as well as a hypersensitivity to exogenous vasopressin. In 2010, Gordon et al. published a post hoc analysis of the VASST trial and demonstrated that the mortality rates in patients with septic shock in the RIFLE “Risk” category were lower in those treated with vasopressin, but this did not reach significance in a multiple logistic regression analysis. In 2015, the VANISH study results were presented, demonstrating that early vasopressin reduced the use of renal replacement therapy in patients with septic shock but did not reduce the number of renal failure-free days or mortality.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gordon AC (2011) Vasopressin in septic shock. J Intensive Care Soc 12:11–14
Sharman A, Low J (2008) Vasopressin and its role in critical care. Contin Educ Anaesth Crit Care Pain 8:134–137
Holmes CL, Patel BM, Russell JA, Walley KR (2001) Physiology of vasopressin relevant to management of septic shock. Chest 120:989–1002
Mohring J, Glanzer K, Maciel JA Jr et al (1980) Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension. J Cardiovasc Pharmacol 2:367–376
Landry DW, Levin HR, Gallant EM et al (1997) Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 27:1416–1421
Holmes CL, Walley KR, Chittock DR et al (2001) The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27:1416–1421
Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96:576–582
Lauzier F, Levy B, Lamarre P et al (2006) Vasopressin or norepinephrine in early haemodynamic septic shock: a randomized clinical trial. Intensive Care Med 32:1783–1789
Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887
Gordon AC, Russell JA, Walley KR et al (2010) The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36:83–91
Gordon AC et al (2015) Vasopressin vs Noradrenaline as Initial Therapy in Septic Shock (VANISH): a randomized controlled trial. In: Hot topics session. Symposium conducted at the European Society for Intensive Care Medicine (ESICM) lives 2015 conference, Berlin
Gordon AC, Mason AJ, Perkins GD et al (2014) Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open 4:e005866
Kiser TH, Fish DN, Obritsch MD et al (2005) Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. Nephrol Dial Transplant 20:1813–1820
Torgersen C, Dunser MW, Wenzel V et al (2010) Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open label trial. Intensive Care Med 36:57–65
Landoni G, Bove T, Székely A et al (2013) Reducing mortality in acute kidney injury patients: systematic review and international web-based survey. J Cardiothorac Vasc Anesth 27:1384–1398
Russell JA, Walley KR, Gordon AC et al (2009) Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care 37:811–818
Annane D (2009) Vasopressin plus corticosteroids: the shock duo! Crit Care Med 37:1126–1127
Gordon AC, Mason AJ, Perkins GD et al (2014) The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. Crit Care Med 42:1325–1333
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Christie, L.E., Hayes, M.A. (2016). Vasopressin to Reduce Mortality in Patients with Septic Shock and Acute Kidney Injury. In: Landoni, G., Pisano, A., Zangrillo, A., Bellomo, R. (eds) Reducing Mortality in Acute Kidney Injury. Springer, Cham. https://doi.org/10.1007/978-3-319-33429-5_14
Download citation
DOI: https://doi.org/10.1007/978-3-319-33429-5_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33427-1
Online ISBN: 978-3-319-33429-5
eBook Packages: MedicineMedicine (R0)